NL-OMON31546已完成不适用
A Phase 1 Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of the Selective Met Inhibitor, JNJ 38877605 in Subjects With Advanced or Refractory Solid Tumors. - N/A
Johnson & Johnson Pharmaceutical0 个研究点目标入组 33 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •histologically or cytologically confirmed advanced or refractory solid
- •tumor and no longer eligible for approved, available standard therapies
排除标准
- •known brain metastases
研究者
相似试验
尚未招募
不适用
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid TumoursNL-OMON51802DeuterOncology NV15
招募中
不适用
A Phase 1 trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies.relapsed or refractory lymphoid malignancy, relapsed/refractory multiple myeloma, relapsed/refractory Hodgkins lymphoma, relapsed/refractory peripheral T-cell lymphoma, relapsed/refractory cutaneous T-cell lymphoma, subtypes mycosis fungoides and Sézary syndrome, relapsed/refractory T-cell Prolymphocytic leukemia. Note: Recruitment to the CTCL and T-PLL cohorts was halted on 01 March 2021.Relapsed/ refractory Hematologic Malignancies10025319NL-OMON52700Mundipharma Research Limited10
尚未招募
1 期
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000808549Bluejay Therapeutics, Inc40
尚未招募
1 期
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624000809538Bluejay Therapeutics, Inc80
未知
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients with Advanced or Refractory Solid Tumors or LymphomaJPRN-jRCT2080223021Janssen Pharmaceutical K.K.33